Journal of Infection and Public Health
Volume 2, Issue 2 , Pages 74-80 , 2009

Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt

  • Kenneth C. Earhart

      Affiliations

    • U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt
    • I am an employee of the U.S. Government. This work was prepared as part of my official duties. Title 17 U.S.C. §105 provides that ‘Copyright protection under this title is not available for any work of the United States Government’ Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties.
    • Corresponding Author InformationCorresponding author. United States Naval Medical Research Unit No. 3, PSC 452 Box 5000, MDS - Code 303, FPO AE 09835-0007, Egypt. Tel.: +20 223421381; fax: +20 223421382.
    • ,
  • Nasr M. Elsayed

      Affiliations

    • Ministry of Health, Cairo, Egypt
    • ,
  • Magdi D. Saad

      Affiliations

    • U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt
    • ,
  • Larisa V. Gubareva

      Affiliations

    • U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
    • ,
  • Ahmed Nayel

      Affiliations

    • Ministry of Health, Cairo, Egypt
    • ,
  • Varough M. Deyde

      Affiliations

    • U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
    • ,
  • Ali Abdelsattar

      Affiliations

    • Ministry of Health, Cairo, Egypt
    • ,
  • Ahmad S. Abdelghani

      Affiliations

    • Ministry of Health, Cairo, Egypt
    • ,
  • Bruce R. Boynton

      Affiliations

    • U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt
    • ,
  • Moustafa M. Mansour

      Affiliations

    • U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt
    • ,
  • Hala M. Essmat

      Affiliations

    • Ministry of Health, Cairo, Egypt
    • ,
  • Alexander Klimov

      Affiliations

    • U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
    • ,
  • Deidra Shuck-Lee

      Affiliations

    • U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt
    • ,
  • M.R. Monteville

      Affiliations

    • U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt
    • ,
  • Jeffrey A. Tjaden

      Affiliations

    • U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt

Received 23 February 2009 ,Revised 30 March 2009 ,Accepted 1 April 2009.

Reference 

  1. Yingst SL, Saad MD, Felt SA. Qinghai-like A(H5N1) from domestic cats, northern Iraq. Emerg Infect Dis. 2006;12(August (8)):1295–1297
  2. World Health Organization (WHO). Clinical management of human infection with avian influenza A(H5N1) virus: http://www.who.int/csr/disease/avian_influenza/guidelines/ClinicalManagement07.pdf.
  3. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antiviral Therapy. 2007;12:603–616
  4. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008;13:pii: 8026
  5. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infection with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA. 2009;301(March (10)):1034–1041
  6. Besselaar TG, Naidoo D, Buys A, et al. Widespread oseltamivir resistance in influenza A viruses (H5N1), South Africa. EID 2008 11 November;14(11):1809-10.
  7. World Health Organization. Influenza A(H5N1) virus resistance to oseltamivir – 2008/2009 influenza season, northern hemisphere: http://www.who.int/csr/disease/influenza/H1N1webupdate20090318%20ed_ns.pdf.
  8. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353(December (25)):2667–2672
  9. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437(October (7062)):1108
  10. Spackman E, Senne DA, Myers TJ, et al. Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J. Clin. Microbiol. 2002;40(September (9)):3256–3260
  11. Payungporn S, Chutinimitkul S, Chaisingh A, et al. Single step multiplex real-time RT-PCR for A(H5N1) influenza A virus detection. J Virol Methods. 2006;131(February (2)):143–147
  12. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp. 1999;41:95–98
  13. Kumar S, Tamura K, Nei M. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform. 2004;5(June (2)):150–163
  14. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol. 2003;41(February (2)):742–750
  15. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Research. 2002;53(January (1)):47–61
  16. Aymard-Henry M, Coleman MT, Dowdle WR, et al. Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull World Health Organ. 1973;48(2):199–202
  17. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364(August (9436)):759–765
  18. Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis. 2001;183(4):523–531
  19. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366(October (9492)):1175–1181
  20. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295(Febrauary (8)):891–894
  21. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007;196(July (2)):249–257
  22. Barr IG, Hurt AC, Deed N, et al. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antiviral Res. 2007;75:173–176
  23. Saito R, Li D, Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005–2006. N Engl J Med. 2007;356:312–313
  24. Cheung CL, Rayner JM, Smith GJ, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis. 2006;193:1626–1629
  25. Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem. 2000;43(19):3482–3486
  26. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283(8):1016–1024
  27. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006;443(7107):45–49
  28. Smith BJ, Kimm-Breshkin JL, McDonald M, et al. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem. 2002;45(11):2207–2212
  29. Rayner CR, Chanu P, Gieschke R, et al. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharm,. 2008. doi:10.1177/0091270008320317.

☆ Disclaimer: The views and opinions expressed herein do not necessarily represent those of the U.S. Army or U.S. Navy or the Department of Defense.

PII: S1876-0341(09)00031-8

doi: 10.1016/j.jiph.2009.04.004

Journal of Infection and Public Health
Volume 2, Issue 2 , Pages 74-80 , 2009

Article Tools

* Image Usage & Resolution